One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug companies will go public on the stock market.
“It will definitely change in 2026. We will see a lot more IPOs, is my prediction, than we’ve seen here this year and last year — two very barren years for IPOs,” Bruce Booth, a partner at Atlas Venture, who has been investing in biotechs for two decades, told the hosts of “The Readout LOUD,” STAT’s weekly biotech podcast.
Initial public offerings, or IPOs, are one of the signs of the biotech sector’s health: In years when Wall Street traders welcome longer-term pharmaceutical bets and private market investors sense they can get a nice profit, startups will offer up their stock for anyone to buy on Nasdaq or the New York Stock Exchange. (Nasdaq has generally been the stock market of choice for drug companies.)
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
